FindTrial
Sign In

S95032/AG-881

DRUG3 trials

Sponsors

Institut De Recherches Internationales Servier IRIS, Europese Organisatie Voor Onderzoek En Behandeling Van Kanker Organisation Europeenne Pour La Recherche Et Le Traitement Du Cancer European Organi

Conditions

IDH1-mutant GliomaIDH2-mutant GliomaResidual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation​​IDH-mutant grade 2 or 3 astrocytoma​

Phase 1

A Phase 1b/2, multicenter study of vorasidenib in combination with temozolomide (TMZ) in participants with IDH1- or IDH2-mutant glioma
Active, not recruitingCTIS2024-513738-39-00
Institut De Recherches Internationales Servier IRISIDH1-mutant Glioma, IDH2-mutant Glioma
Start: 2025-03-18Target: 17Updated: 2025-12-18

Phase 3

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation
Active, not recruitingCTIS2024-512961-15-00
Institut De Recherches Internationales Servier IRISResidual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation
Start: 2020-08-05Target: 71Updated: 2025-07-30
EORTC-2427-BTG: Vorasidenib as maintenance treatment after first-line chemoradiotherapy in IDH-mutant grade 2 or 3 astrocytoma: a placebo-controlled, triple-blind, randomized phase III study (VIGOR)
RecruitingCTIS2024-519404-27-00
Europese Organisatie Voor Onderzoek En Behandeling Van Kanker Organisation Europeenne Pour La Recherche Et Le Traitement Du Cancer European Organi​​IDH-mutant grade 2 or 3 astrocytoma​
Start: 2026-01-16Target: 247Updated: 2025-11-10

Related Papers

CTNI-09. VORASIDENIB AS MAINTENANCE TREATMENT AFTER FIRST-LINE CHEMORADIOTHERAPY IN IDH-MUTANT GRADE 2/3 ASTROCYTOMA: STUDY PROTOCOL FOR THE PLACEBO-CONTROLLED, TRIPLE-BLIND, RANDOMIZED PHASE III STUDY EORTC-2427 (VIGOR)
Neuro-Oncology2025-11-01
P17.06.A VORASIDENIB AS MAINTENANCE TREATMENT AFTER FIRST-LINE CHEMORADIOTHERAPY IN IDH-MUTANT GRADE 2/3 ASTROCYTOMA: STUDY PROTOCOL FOR THE PLACEBO-CONTROLLED, TRIPLE-BLIND, RANDOMIZED PHASE III STUDY EORTC-2427 (VIGOR)
Neuro-Oncology2025-10-01